News & Updates

The transcatheter valve-in-valve (ViV) procedure appears to be a safe option for select patients requiring repeat surgery after failed mitral bioprostheses, according to findings from the randomized controlled SURViV trial presented at ACC.26. However, it is still early days for the ViV approach.

Once-daily application of roflumilast cream 0.3% is associated with a significantly higher rate of treatment success on the Investigator's Global Assessment (IGA) scale in Chinese patients with plaque psoriasis compared with a vehicle cream, according to the phase III DERMIS-1 and -2 studies presented at AAD 2026.

Patients with psoriasis appear to have the lowest risk of developing psoriatic arthritis (PsA) when they are treated with IL-23 inhibitors than with other immunomodulatory agents, according to a real-world study.

Patients with cutaneous malignant melanoma (CMM) whose tumour is located in the head and neck (HN) are at greater risk of all-cause and cancer-specific mortality than those with tumours found in the trunk, reveals a study.

Administrating pegfilgrastim 72 h after chemotherapy, compared with 24- and 48-h administration, results in reduced pegfilgrastim-induced bone pain (PIBP) and does not appear to increase the rates of neutropenia or febrile neutropenia (FN), reports a study.

The first-in-class KRAS G12D–targeted protein degrader setidegrasib has demonstrated antitumour activity in patients with previously treated advanced non–small-cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma harbouring the KRAS G12D mutation, according to a phase I study.

Treatment with tirzepatide, a dual GLP-1* and GIP** agonist, significantly improves cardiovascular and renal outcomes in patients with diabetes and atherosclerotic cardiovascular disease (ASCVD) compared with dulaglutide, according to a post hoc analysis of the SURPASS-CVOT trial presented at ACC.26.

Stopping beta-blockers after a year of regular use does not appear to increase the risk of adverse clinical outcomes in myocardial infarction (MI) survivors without evidence of left ventricular systolic dysfunction or heart failure (HF), as shown in the SMART-DECISION trial.